Antimalarials in the Treatment of Schistosomiasis
The DOI matches its Crossref record.
Abstract
With just one drug used for individual patient management and community-based morbidity control, the treatment, control, and eventual elimination of schistosomiasis is vulnerable should resistance to praziquantel emerge and spread. The discovery and development of novel chemical entities that exhibit antischistosomal properties, and the repurposing of existing drugs for schistosomiasis is thus of central importance as long as praziquantel remains effective. Here, we discuss the public health relevance of schistosomiasis, which is currently considered a neglected tropical disease. We recapitulate the past and current drug armamentarium against schistosomiasis, including shortcomings and a target product profile of an antischistosomal drug. The central piece of our review is the discovery of the antischistosomal properties of various antimalarial drugs, notably the artemisinins, synthetic trioxolanes, and mefloquine. We summarize findings from preclinical investigations and experiences made thus far from clinical studies. We conclude that a closer collaboration between the malaria and schistosomiasis communities might facilitate the discovery and development of novel antischistosomal drugs, and will foster monitoring and evaluation of the ancillary benefits of antimalarial prophylaxis and treatment against schistosomiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Time to set the agenda for schistosomiasis elimination
Rollinson, D., Knopp, S., Levitz, S., Stothard, J. R., Tchuem Tchuenté, L.-A., Garba, A., Mohammed, K. A., Schur, N., Person, B., Colley, D. G., et al. (2013) · Acta Tropica · doi:10.1016/j.actatropica.2012.04.013 · Cited by 617
The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases
Cheuka, P., Mayoka, G., Mutai, P., & Chibale, K. (2016) · Molecules · doi:10.3390/molecules22010058 · Cited by 222
“The public health impact of schistosomiasis is revealed by records showing that the infection is only second to malaria with respect to epidemiology and morbidity among the parasitic diseases [165].”
BackgroundControlling schistosomiasis with praziquantel: How much longer without a viable alternative?
Bergquist, R., Utzinger, J., & Keiser, J. (2017) · Infectious Diseases of Poverty · doi:10.1186/s40249-017-0286-2 · Cited by 195
“While the antimalarials are the most well-known group of drugs shown to have a strong action against schistosomes in addition to what they are intended for [49] several other pharmaceutical groups also contain compounds with such effect, notably drugs used for cancer therapy [51].”
BackgroundSelf-citationMunyangi, J., Cornet-Vernet, L., Idumbo, M., Lu, C., Lutgen, P., Perronne, C., Ngombe, N., Bianga, J., Mupenda, B., Lalukala, P., et al. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.10.014 · Cited by 40
RetractedMontoya, M. C., Beattie, S., Alden, K. M., & Krysan, D. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-19 · Cited by 42
“MEF has also been studied as a repurposing candidate against other human 90 parasites including schistosomiasis, toxoplasmosis, and echinococcosis (11-17).”
Background
Metadata
- Authors
- Keiser, J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012
- Volume
- 18
- Issue
- 24
- Pages
- 3531-8
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1965049762
- Cited by
- 93
- References
- 0
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimalarials in the Treatment of Schistosomiasis. https://app.cochat.ai/papers/10.2174/138161212801327293
- The paper
- Keiser, J. (2012). Antimalarials in the Treatment of Schistosomiasis. Current Pharmaceutical Design. https://doi.org/10.2174/138161212801327293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.